{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:14:39Z","timestamp":1777594479750,"version":"3.51.4"},"reference-count":30,"publisher":"Impact Journals, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2024,2,8]]},"DOI":"10.18632\/oncotarget.28557","type":"journal-article","created":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T13:40:46Z","timestamp":1707399646000},"page":"124-133","source":"Crossref","is-referenced-by-count":1,"title":["GZ17-6.02 interacts with bexarotene to kill mycosis fungoides cells"],"prefix":"10.18632","volume":"15","author":[{"given":"Michael R.","family":"Booth","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA 23298, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Booth","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA 23298, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane L.","family":"Roberts","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA 23298, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cameron","family":"West","sequence":"additional","affiliation":[{"name":"Genzada Pharmaceuticals, Hutchinson, KS 67502, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Dent","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA 23298, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2024,2,8]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/ajh.26760","article-title":"Cutaneous T-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management","volume":"9","author":"Wilcox","year":"2023","journal-title":"Am J Hematol"},{"key":"2","doi-asserted-by":"publisher","first-page":"2","DOI":"10.12788\/j.sder.2018.002","article-title":"Mycosis fungoides-clinical and histopathologic features, differential diagnosis, and treatment","volume":"3","author":"Cerroni","year":"2018","journal-title":"Semin Cutan Med Surg"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.07.049","article-title":"Primary cutaneous T-cell lymphoma (mycosis fungoides and S\u00e9zary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers","volume":"7","author":"Querfeld","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"4","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","article-title":"Clinical end points and response criteria in mycosis fungoides and S\u00e9zary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer","volume":"2","author":"Bagot","year":"2011","journal-title":"J Clin Oncol"},{"key":"5","doi-asserted-by":"publisher","first-page":"adv00013","DOI":"10.2340\/00015555-3367","article-title":"Early-stage Mycosis Fungoides: Epidemiology and Prognosis","volume":"10","author":"Thornton","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"6","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.clindermatol.2019.01.004","article-title":"Mycosis fungoides: A great imitator","volume":"3","author":"Amitay-Laish","year":"2019","journal-title":"Clin Dermatol"},{"key":"7","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1111\/jdv.17570","article-title":"Quality of life in patients with Mycosis Fungoides and S\u00e9zary Syndrome: a systematic review of the literature","volume":"3","author":"Quint","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"8","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1002\/cncr.22252","article-title":"Significant impact of cutaneous T-cell lymphoma on patients\u2019 quality of life: results of a 2005 National Cutaneous Lymphoma Foundation Survey","volume":"10","author":"Miller","year":"2006","journal-title":"Cancer"},{"key":"9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jdin.2022.07.007","article-title":"Itch in patients with cutaneous T-cell lymphoma as a quality of life indicator","volume":"9","author":"Quint","year":"2022","journal-title":"JAAD Int"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.08.033","article-title":"Primary cutaneous T-cell lymphoma (mycosis fungoides and S\u00e9zary syndrome): part II. Prognosis, management, and future directions","volume":"7","author":"Querfeld","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"11","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1177\/1203475419840629","article-title":"Existing and Emerging Therapies for Cutaneous T-Cell Lymphoma","volume":"2","author":"Zhou","year":"2019","journal-title":"J Cutan Med Surg"},{"key":"12","doi-asserted-by":"publisher","first-page":"12163","DOI":"10.1038\/s41598-018-29683-1","article-title":"Potent Antitumor Effects of a Combination of Three Nutraceutical Compounds","volume":"8","author":"Tsue","year":"2018","journal-title":"Sci Rep"},{"key":"13","doi-asserted-by":"publisher","first-page":"194","DOI":"10.38212\/2224-6614.3454","article-title":"The therapeutic potential of curcumin and its related substances in turmeric: From raw material selection to application strategies","volume":"3","author":"Pan","year":"2023","journal-title":"J Food Drug Anal"},{"key":"14","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.3390\/pharmaceutics15041275","article-title":"Exploring the Contribution of Curcumin to Cancer Therapy: A Systematic Review of Randomized Controlled Trials","volume":"1","author":"Mancuso","year":"2023","journal-title":"Pharmaceutics"},{"key":"15","doi-asserted-by":"publisher","first-page":"6862","DOI":"10.1002\/jcp.29580","article-title":"(Curcumin+sildenafil) enhances the efficacy of 5FU and anti-PD1 therapies in vivo","volume":"23","author":"Hancock","year":"2020","journal-title":"J Cell Physiol"},{"key":"16","doi-asserted-by":"publisher","first-page":"8098","DOI":"10.1002\/jcp.29464","article-title":"GZ17-6.02 initiates DNA damage causing autophagosome-dependent HDAC degradation resulting in enhanced anti-PD1 checkpoint inhibitory antibody efficacy","volume":"23","author":"Dent","year":"2020","journal-title":"J Cell Physiol"},{"key":"17","doi-asserted-by":"publisher","first-page":"711043","DOI":"10.3389\/fonc.2021.711043","article-title":"GZ17-6.02 and Pemetrexed Interact to Kill Osimertinib-Resistant NSCLC Cells That Express Mutant ERBB1 Proteins","volume":"1","author":"Dent","year":"2021","journal-title":"Front Oncol"},{"key":"18","doi-asserted-by":"publisher","first-page":"656453","DOI":"10.3389\/fonc.2021.656453","article-title":"GZ17-6.02 Interacts With [MEK1\/2 and B-RAF Inhibitors] to Kill Melanoma Cells","volume":"1","author":"Dent","year":"2021","journal-title":"Front Oncol"},{"key":"19","doi-asserted-by":"publisher","first-page":"92","DOI":"10.18632\/oncotarget.28177","article-title":"GZ17-6.02 and palbociclib interact to kill ER+ breast cancer cells","volume":"1","author":"Dent","year":"2022","journal-title":"Oncotarget"},{"key":"20","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1080\/09546634.2020.1764905","article-title":"A novel plant-derived compound is synergistic with 5-fluorouracil and has increased apoptotic activity through autophagy in the treatment of actinic keratoses","volume":"3","author":"Dent","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"21","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1097\/CAD.0000000000001425","article-title":"A novel combination of isovanillin, curcumin, and harmine (GZ17-6.02) enhances cell death and alters signaling in actinic keratoses cells when compared to individual components and two-component combinations","volume":"3","author":"Dent","year":"2023","journal-title":"Anticancer Drugs"},{"key":"22","doi-asserted-by":"publisher","first-page":"1045459","DOI":"10.3389\/fonc.2022.1045459","article-title":"GZ17-6.02 kills prostate cancer cellsand","volume":"1","author":"Dent","year":"2022","journal-title":"Front Oncol"},{"key":"23","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/CAD.0000000000001203","article-title":"Mechanisms of GZ17-6.02 resistance","volume":"3","author":"Dent","year":"2022","journal-title":"Anticancer Drugs"},{"key":"24","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.3389\/fonc.2020.01331","article-title":"GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells via Autophagy and Death Receptor Signaling","volume":"1","author":"Dent","year":"2020","journal-title":"Front Oncol"},{"key":"25","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jep.2016.04.038","article-title":"Complementary and alternative medicine use among cancer patients in Palestine with special reference to safety-related concerns","volume":"18","author":"Hamadeh","year":"2016","journal-title":"J Ethnopharmacol"},{"key":"26","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1080\/15384047.2015.1078021","article-title":"Harmine suppresses homologous recombination repair and inhibits proliferation of hepatoma cells","volume":"1","author":"Jiang","year":"2015","journal-title":"Cancer Biol Ther"},{"key":"27","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1002\/ptr.2860","article-title":"The beta-carboline alkaloid harmine inhibits BCRP and can reverse resistance to the anticancer drugs mitoxantrone and camptothecin in breast cancer cells","volume":"2","author":"Wink","year":"2010","journal-title":"Phytother Res"},{"key":"28","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/j.freeradbiomed.2007.08.018","article-title":"Structure-activity relationship of C6-C3 phenylpropanoids on xanthine oxidase-inhibiting and free radical-scavenging activities","volume":"4","author":"Lin","year":"2007","journal-title":"Free Radic Biol Med"},{"key":"29","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/s0027-5107(01)00294-9","article-title":"Genotoxic and recombinogenic activities of the two beta-carboline alkaloids harman and harmine in Saccharomyces cerevisiae","volume":"50","author":"Henriques","year":"2002","journal-title":"Mutat Res"},{"key":"30","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jep.2017.03.049","article-title":"A review on traditional uses, phytochemistry, pharmacology, pharmacokinetics and toxicology of the genus Peganum","volume":"20","author":"Wang","year":"2017","journal-title":"J Ethnopharmacol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28557","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T13:40:52Z","timestamp":1707399652000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,8]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2,8]]}},"alternative-id":["28557"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.28557","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,8]]}}}